Eli Lilly and Company (NYSE:LLY) expects 2025 revenue of between $58.0 billion – $61.0 billion. The midpoint demonstrates ~32% growth YoY, fueled by new Lilly medicines like Zepbound ...

Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly ... stories. Lilly beat fourth-quarter estimates for earnings as well as sales. Sales of Lilly’s incretin medicines, Mounjaro, Trulicity ...

Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's revenue ...

Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. 1. Time and money ...

Eli Lilly's weight-loss drugs include Mounjaro and Zepbound.Sandy Huffaker for The Washington Post/Getty Images Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.

On Wednesday, a federal judge ruled that compounding pharmacies must stop selling versions of Eli Lilly's Zepbound and Mounjaro. The FDA removed its active ingredient, tirzepatide, from a shortage ...